Source-grounded facts extracted from Lexaria Bioscience Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lexaria Bioscience Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).”
Lexaria Bioscience Corp. entered into Purchase Agreement with certain institutional investors valued at approximately $3.5 million (effective 2025-12-14).
“On December 14, 2025, Lexaria Bioscience Corp., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company issued and sold to the investors (i) in a registered direct offering, 2,661,600 shares (the “Shares”) of Common Stock, par value $0.001 per share of the Company (the “Common Stock”) at a price of $1.315 per share, and (ii) in a concurrent private placement, 2,661,600 common stock purchase warrants (the “Private Placement Warrants”), exercisable for an aggregate of up to 2,661,600 shares of Common Stock, at an exercise price of $1.19 per share of Common Stock.”
Lexaria Bioscience Corp. issued 93,156 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC or its designees for exercise price of $1.6438 per share.
“number of Shares issued and sold on the Closing Date. The Placement Agent Warrants expire five years from the commencement of sales of the Offering and have an exercise price of $1.6438 per share of Common Stock armel, LLP, securities counsel to the Company, delivered an opinion as to the validity of the Shares, a copy of which is filed as Exhibit 5.1 to this”
Lexaria Bioscience Corp. issued up to 2,661,600 shares of Common Stock of warrant to certain institutional investors for exercise price of $1.19 per share.
“in a concurrent private placement, 2,661,600 common stock purchase warrants (the “Private Placement Warrants”), exercisable for an aggregate of up to 2,661,600 shares of Common Stock, at an exercise price of $1.19 per share of Common Stock”
Lexaria Bioscience Corp. issued 2,661,600 shares of common stock to certain institutional investors for $1.315 per share.
“the Company issued and sold to the investors (i) in a registered direct offering, 2,661,600 shares (the “Shares”) of Common Stock, par value $0.001 per share of the Company (the “Common Stock”) at a price of $1.315 per share”
Lexaria Bioscience Corp. issued 93,333 common stock warrants to purchase up to 93,333 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC for exercise price of $1.875 per share of Common Stock.
“number of Shares issued and sold on the Closing Date. The Placement Agent Warrants expire five years from the commencement of sales of the Offering and have an exercise price of $1.875 per share of Common Stock. armel, LLP, securities counsel to the Company, delivered an opinion as to the validity of the Shares, a copy of which is filed as Exhibit 5.1 to this”
Lexaria Bioscience Corp. issued 2,666,667 common stock purchase warrants of warrant to certain institutional investors for exercise price of $1.37 per share of Common Stock.
“and (ii) in a concurrent private placement, 2,666,667 common stock purchase warrants (the “Private Placement Warrants”), exercisable for an aggregate of up to 2,666,667 shares of Common Stock, at an exercise price of $1.37 per share of Common Stock.”
Richard Christopher changed role as principal financial officer (interim) at Lexaria Bioscience Corp..
“Richard Christopher, the Company’s Chief Executive Officer who assumed the responsibilities as the Company’s principal financial officer on an interim basis, relinquished those responsibilities to Mr. Shankman.”
Nelson Cabatuan resigned as Chief Financial Officer at Lexaria Bioscience Corp..
“replacing Lexaria’s former CFO, Nelson Cabatuan who resigned effective July 15, 2024”
Michael Shankman was appointed as Chief Financial Officer at Lexaria Bioscience Corp..
“Effective October 1, 2024, Michael Shankman, age 64, has been appointed to the position of Chief Financial Officer of Lexaria Bioscience Corp.”
Christopher Bunka changed role as Chairman of the Board at Lexaria Bioscience Corp..
“replacing Christopher Bunka who will remain as the Company’s Chairman of the Board and as a strategic advisor”
Richard Christopher was appointed as Chief Executive Officer at Lexaria Bioscience Corp..
“appointed Richard Christopher, age 54, to the position of Chief Executive Officer”
Nelson Cabatuan resigned as Chief Financial Officer at Lexaria Bioscience Corp..
“Effective on July 15, 2024, Mr. Nelson Cabatuan resigned from his position as the Company’s Chief Financial Officer in order to focus his attention on corporate finance and strategic industry relationships for Lexaria as its Chief Strategic Financial Advisor.”
Lexaria Bioscience Corp. entered into Warrant Exercise Agreement with an existing accredited investor valued at approximately $4.7 million (effective 2024-04-30).
“On April 30, 2024, Lexaria Bioscience Corp. (the “Company”) entered into a warrant exercise agreement (the “Warrant Exercise Agreement”) with an existing accredited investor (the “Investor”) to exercise in full an outstanding Common Stock Purchase Warrant (the “Exercise”) to purchase up to an aggregate of 2,917,032 shares of the Company’s common stock (the “Existing Warrant”).”
Lexaria Bioscience Corp. shareholders approved To Ratify the lawful actions of the directors for the past year at the 2024-04-23 meeting.
“To Ratify the lawful actions of the directors for the past year 4,110,965 67,011 54,505 2,432,746 97 %”
Lexaria Bioscience Corp. shareholders approved To Appoint Malone Bailey LLP as Auditors at the 2024-04-23 meeting.
“To Appoint Malone Bailey LLP as Auditors 6,566,179 59,519 39,529 0 99 %”
Lexaria Bioscience Corp. shareholders approved Election of Directors at the 2024-04-23 meeting.
“To Elect Chris Bunka as a director 4,188,641 43,840 N/A 2,432,746 99 % To Elect John Docherty as a director 4,189,577 42,904 N/A 2,432,746 99 % To Elect Nicholas Baxter as a director 4,161,194 71,287 N/A 2,432,746 98 % To Elect Ted McKechnie as a director 3,735,858 496,623 N/A 2,432,746 88 % To Elect Albert Reese Jr. as a director 3,603,029 629,452 N/A 2,432,746 85 % To Elect Dr. Catherine Turkel as a director 4,181,783 50,698 N/A 2,432,746 99 %”
Nelson Cabatuan was appointed as Chief Financial Officer at Lexaria Bioscience Corp..
“Effective March 14, 2024, Nelson Cabatuan, age 46, has been appointed to the position of Chief Financial Officer of Lexaria Bioscience Corp.”
Lexaria Bioscience Corp. entered into Engagement Agreement with H.C. Wainwright & Co., LLC (effective 2024-02-12).
“In connection with the Offering, on February 12, 2024, the Company entered into an engagement agreement (the “Engagement Agreement”) with H.C. Wainwright & Co., LLC (the “Placement Agent”).”
Lexaria Bioscience Corp. entered into securities purchase agreement with certain institutional investors valued at approximately $3.6 million (effective 2024-02-14).
“On February 14, 2024, Lexaria Bioscience Corp., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “SPA”) with certain institutional investors”
Lexaria Bioscience Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“October 17, 2023, Lexaria Bioscience Corp. (the “Company”) received a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Bid Price Deficiency Notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on the Nasdaq Capital Market”
Lexaria Bioscience Corp. shareholders approved To approve a reverse stock split with such ratio to be not less than 2 current shares for one post reverse stock split share and no more than 12 current shares for one post reverse stock split. at the 2023-10-10 meeting.
“Matter Being Voted On For Against/ Withheld Abstain Broker Non-Vote Percent Approved By 1 To Approve a Reverse Stock Split with such ratio to be not less than 2 current shares for one post reverse stock split share and no more than 12 current shares for one post reverse stock split. 3,120,754 1,546,507 13,453 0 67 %”
Lexaria Bioscience Corp. entered into SPA with a certain institutional investor valued at $1,569,780.10 (effective 2023-09-28).
“On September 28, 2023, Lexaria Bioscience Corp., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “SPA”) with a certain institutional investor”
Lexaria Bioscience Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“June 22, 2023, Lexaria Bioscience Corp. (the “Company”) received a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Bid Price Deficiency Notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on the Nasdaq Capital Market un”
Chris Bunka changed role as Principal Financial Officer at Lexaria Bioscience Corp..
“The Company’s Chief Executive Officer, Chris Bunka, will assume the role of principal financial officer at this time.”
Gregory Downey departed as Chief Financial Officer at Lexaria Bioscience Corp..
“Effective June 6, 2023, Mr. Gregory Downey was dismissed as the Company’s Chief Financial Officer.”
Lexaria Bioscience Corp. entered into Security Purchase Agreement with certain institutional investors valued at up to an aggregate of $247,000 of Units (effective 2023-05-08).
“On May 8, 2023, the Company also entered into a security purchase agreement (the “Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”) in connection with the Offering.”
Lexaria Bioscience Corp. entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-05-08).
“On May 8, 2023, Lexaria Bioscience Corp. (the “Company”) entered into a placement agency agreement dated as of May 8, 2023 (the “PAA”) with Maxim Group LLC (the “Placement Agent”)”
Lexaria Bioscience Corp. shareholders approved To Ratify the lawful actions of the directors for the past year at the 2023-05-09 meeting.
“To Ratify the lawful actions of the directors for the past year 2,005,926 156,382 57,145 1,152,571 90.4%”
Lexaria Bioscience Corp. shareholders approved To Approve the Addition of an Evergreen Formula to the Incentive Equity Plan at the 2023-05-09 meeting.
“To Approve the Addition of an Evergreen Formula to the Incentive Equity Plan 1,400,723 709,940 108,790 1,152,571 63.1%”
Lexaria Bioscience Corp. shareholders approved To Approve the Amendment to the Maxim Number of Shares Issuable pursuant to the Incentive Equity Plan at the 2023-05-09 meeting.
“To Approve the Amendment to the Maxim Number of Shares Issuable pursuant to the Incentive Equity Plan 1,965,779 249,519 4,155 1,152,571 88.6%”
Lexaria Bioscience Corp. shareholders approved To Approve the Stock Option Repricing at the 2023-05-09 meeting.
“To Approve the Stock Option Repricing 1,529,271 677,686 12,429 1,152,638 68.9%”
Lexaria Bioscience Corp. shareholders approved To Appoint Malone Bailey LLP as Auditors at the 2023-05-09 meeting.
“To Appoint Malone Bailey LLP as Auditors 3,249,199 105,067 17,758 96.4%”
Lexaria Bioscience Corp. shareholders approved Election of Directors at the 2023-05-09 meeting.
“To Elect Chris Bunka as a director 2,141,964 77,489 1,152,571 96.5% To Elect John Docherty as a director 2,137,546 81,907 1,152,571 96.3% To Elect Nicholas Baxter as a director 1,648,288 571,165 1,152,571 74.3% To Elect Ted McKechnie as a director 2,123,869 95,584 1,152,571 95.7% To Elect Albert Reese Jr. as a director 2,134,837 84,683 1,152,504 96.2% To Elect Dr. Catherine Turkel as a director 2,165,426 54,027 1,152,571 97.6%”
Lexaria Bioscience Corp. engaged MaloneBailey LLP as its auditor.
“the Board of Directors accepted this recommendation and approved the appointment of MaloneBailey effective as of November 25, 2022.”
Davidson & Company LLP resigned as auditor of Lexaria Bioscience Corp..
“Davidson & Company LLP (“Davidson & Co.”), advised Lexaria Bioscience Corp. (the “Registrant”) that it would not stand for re-election as the Registrant’s Certifying Accountant after completing its audit of the Registrant’s year end financial statements.”
Catherine C. Turkel was appointed as Independent Director at Lexaria Bioscience Corp..
“On September 2, 2022 (the “Effective Date”) the board of directors of Lexaria Bioscience Corp., in accordance with Nevada corporate laws, increased the size of the board to six members and appointed Catherine C. Turkel, PharmD, PhD as an additional independent director to hold such position until the next shareholder’s meeting.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.